Omega Therapeutics' Cancer Program Shows Encouraging Anti Tumor Activity In Liver Cancer
Portfolio Pulse from Vandana Singh
Omega Therapeutics Inc (NASDAQ:OMGA) announced preliminary data from its Phase 1/2 MYCHELANGELO I study of OTX-2002 in liver cancer and other solid tumors. The data showed encouraging anti-tumor activity, with on-target engagement and intended epigenetic changes observed in all patients. OTX-2002 was generally well tolerated, with no dose-limiting toxicities. Despite the positive news, OMGA shares are down 14.70% at $2.56.
September 26, 2023 | 4:41 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Despite positive preliminary data from its Phase 1/2 study of OTX-2002, Omega Therapeutics' shares are down 14.70%.
The drop in Omega Therapeutics' share price despite the positive preliminary data from its Phase 1/2 study of OTX-2002 suggests that the market may have expected more from the results, or that other factors are influencing the stock's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100